205 related articles for article (PubMed ID: 36128207)
1. TGF-β1/Smad Signalling in Proliferative Glomerulonephritis Associated with Autoimmune Diseases.
Chalkia A; Gakiopoulou H; Theochari I; Foukas PG; Vassilopoulos D; Petras D
Mediterr J Rheumatol; 2022 Jun; 33(2):176-184. PubMed ID: 36128207
[TBL] [Abstract][Full Text] [Related]
2. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
[TBL] [Abstract][Full Text] [Related]
3. TGF-β: the master regulator of fibrosis.
Meng XM; Nikolic-Paterson DJ; Lan HY
Nat Rev Nephrol; 2016 Jun; 12(6):325-38. PubMed ID: 27108839
[TBL] [Abstract][Full Text] [Related]
4. Transforming Growth Factor-β1/Smad Signaling in Glomerulonephritis and Its Association with Progression to Chronic Kidney Disease.
Chalkia A; Gakiopoulou H; Theohari I; Foukas PG; Vassilopoulos D; Petras D
Am J Nephrol; 2021; 52(8):653-665. PubMed ID: 34496361
[TBL] [Abstract][Full Text] [Related]
5. miR-130a-3p inhibition protects against renal fibrosis in vitro via the TGF-β1/Smad pathway by targeting SnoN.
Ai K; Zhu X; Kang Y; Li H; Zhang L
Exp Mol Pathol; 2020 Feb; 112():104358. PubMed ID: 31836508
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling.
Phanish MK; Wahab NA; Hendry BM; Dockrell ME
Nephron Exp Nephrol; 2005; 100(4):e156-65. PubMed ID: 15855807
[TBL] [Abstract][Full Text] [Related]
7. Anti-fibrotic effects of synthetic TGF-β1 and Smad oligodeoxynucleotide on kidney fibrosis in vivo and in vitro through inhibition of both epithelial dedifferentiation and endothelial-mesenchymal transitions.
Gwon MG; An HJ; Kim JY; Kim WH; Gu H; Kim HJ; Leem J; Jung HJ; Park KK
FASEB J; 2020 Jan; 34(1):333-349. PubMed ID: 31914629
[TBL] [Abstract][Full Text] [Related]
8. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro.
Meng XM; Huang XR; Xiao J; Chen HY; Zhong X; Chung AC; Lan HY
J Pathol; 2012 Jun; 227(2):175-88. PubMed ID: 22190171
[TBL] [Abstract][Full Text] [Related]
9. Role of the TGF-β/BMP-7/Smad pathways in renal diseases.
Meng XM; Chung AC; Lan HY
Clin Sci (Lond); 2013 Feb; 124(4):243-54. PubMed ID: 23126427
[TBL] [Abstract][Full Text] [Related]
10. Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril.
Huang YR; Wei QX; Wan YG; Sun W; Mao ZM; Chen HL; Meng XJ; Shi XM; Tu Y; Zhu Q
J Ethnopharmacol; 2014 Sep; 155(3):1541-52. PubMed ID: 25087615
[TBL] [Abstract][Full Text] [Related]
11. Low-dose of multi-glycoside of Tripterygium wilfordii Hook. f., a natural regulator of TGF-β1/Smad signaling activity improves adriamycin-induced glomerulosclerosis in vivo.
Wan YG; Che XY; Sun W; Huang YR; Meng XJ; Chen HL; Shi XM; Tu Y; Wu W; Liu YL
J Ethnopharmacol; 2014 Feb; 151(3):1079-1089. PubMed ID: 24362077
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta and Smad signalling in kidney diseases.
Wang W; Koka V; Lan HY
Nephrology (Carlton); 2005 Feb; 10(1):48-56. PubMed ID: 15705182
[TBL] [Abstract][Full Text] [Related]
13. Zerumbone, a humulane sesquiterpene from Syringa pinnatifolia, attenuates cardiac fibrosis by inhibiting of the TGF-β1/Smad signaling pathway after myocardial infarction in mice.
Li J; Ge F; Wuken S; Jiao S; Chen P; Huang M; Gao X; Liu J; Tu P; Chai X; Huang L
Phytomedicine; 2022 Jun; 100():154078. PubMed ID: 35405613
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the transforming growth factor-beta 1 signalling pathway as a possible link between hyperphosphataemia and renal fibrosis in feline chronic kidney disease.
Lawson JS; Syme HM; Wheeler-Jones CPD; Elliott J
Vet J; 2021 Jan; 267():105582. PubMed ID: 33375963
[TBL] [Abstract][Full Text] [Related]
15. [The expressions of TGF-beta1 and Smad 2 mRNA on diseased glomeruli and their significance in the development of glomerulosclerosis].
Ruan Y; Zhang Z; Zhang X; Liu C; Guo M
Zhonghua Bing Li Xue Za Zhi; 2002 Aug; 31(4):314-7. PubMed ID: 12417087
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway.
Kim D; Lee AS; Jung YJ; Yang KH; Lee S; Park SK; Kim W; Kang KP
Nephrol Dial Transplant; 2014 Nov; 29(11):2043-53. PubMed ID: 25031017
[TBL] [Abstract][Full Text] [Related]
17. New insights into TGF-β/Smad signaling in tissue fibrosis.
Hu HH; Chen DQ; Wang YN; Feng YL; Cao G; Vaziri ND; Zhao YY
Chem Biol Interact; 2018 Aug; 292():76-83. PubMed ID: 30017632
[TBL] [Abstract][Full Text] [Related]
18. TGF-β signaling via TAK1 pathway: role in kidney fibrosis.
Choi ME; Ding Y; Kim SI
Semin Nephrol; 2012 May; 32(3):244-52. PubMed ID: 22835455
[TBL] [Abstract][Full Text] [Related]
19. Latent TGF-beta1 protects against crescentic glomerulonephritis.
Huang XR; Chung AC; Zhou L; Wang XJ; Lan HY
J Am Soc Nephrol; 2008 Feb; 19(2):233-42. PubMed ID: 18216320
[TBL] [Abstract][Full Text] [Related]
20. Smad7 as a therapeutic agent for chronic kidney diseases.
Lan HY
Front Biosci; 2008 May; 13():4984-92. PubMed ID: 18508563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
